{"id":3399,"date":"2014-09-20T11:47:34","date_gmt":"2014-09-20T09:47:34","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=3399"},"modified":"2014-09-20T12:45:34","modified_gmt":"2014-09-20T10:45:34","slug":"boehringer-in-programma-tagli-per-mille-posti","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/boehringer-in-programma-tagli-per-mille-posti\/","title":{"rendered":"Boehringer plans to cut thousands of jobs"},"content":{"rendered":"

The second largest German pharmaceutical manufacturer, Boehringer Ingelheim<\/a> it has savings in the pipeline that could lead to the cutting of over 1,000 jobs.\u00a0<\/i><\/p>\n

18\/09\/2014 \u2013 Drnet<\/b><\/a><\/p>\n

\"\"The news comes from the Frankfurter Allgemeine Zeitung<\/a>, later confirmed by the company spokesman Philipp Baum:<\/span><\/b>\u00a0\u201dit could well happen that in the medium term the jobs are affected\u201d by the reorganization plan. "But corporate-related layoffs will be avoided," he added.\u00a0According to the newspaper, the pharmaceutical giant is planning a reduction<\/b>\u00a0of 15% of expenses, canceling among other things 600 positions between now and 2016, and the rest in the following two years. Boehringer Ingelheim employs 47,500 people worldwide, 14,000 in Germany. In the first six months of 2014, turnover fell by 7.9% compared to the previous year to 6.5 billion euros.<\/span><\/p>\n

Two areas of the company are expressly excluded from staff reductions:\u00a0<\/b>the first is the Biberach biopharmaceutical company, which produces drugs for other companies; the second instead relates to Ingelheim's own production, which had aroused the attention of the FDA so much as to send a "Warning Letter", repealed only later.\u00a0The interest from the FDA has increased the turnover of that area of the company by about 14 billion euros a year.<\/b><\/span><\/p>\n

Source: Frankfurter Allgemeine Zeitung<\/a><\/p>","protected":false},"excerpt":{"rendered":"

La seconda casa produttrice farmaceutica tedesca, Boehringer Ingelheim ha in cantiere risparmi che potrebbero portare al taglio di oltre 1000 posti.\u00a0 18\/09\/2014 – DottNet La notizia arriva dalla Frankfurter Allgemeine Zeitung, poi confermata dal portavoce dell’azienda Philipp Baum:\u00a0”potrebbe ben accadere che nel medio termine i posti di lavoro siano coinvolti” dal piano di riorganizzazione. ”Ma …<\/p>","protected":false},"author":4,"featured_media":806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[47,27],"class_list":["post-3399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-big-pharma","tag-licenziati"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/3399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=3399"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/3399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/806"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=3399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=3399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=3399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}